Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.

Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, Bhattacharya T, Migueles SA, Wyatt RT, Korber BT, Mascola JR, Connors M.

J Virol. 2010 Feb;84(3):1631-6. doi: 10.1128/JVI.01482-09. Epub 2009 Nov 18.

PMID:
19923174
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.

Hu X, Hong K, Zhao C, Zheng Y, Ma L, Ruan Y, Gao H, Greene K, Sarzotti-Kelsoe M, Montefiori DC, Shao Y.

J Gen Virol. 2012 Oct;93(Pt 10):2267-78. doi: 10.1099/vir.0.043802-0. Epub 2012 Jul 12.

PMID:
22791603
[PubMed - indexed for MEDLINE]
Free Article
3.

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M.

J Virol. 2009 Jan;83(1):188-99. doi: 10.1128/JVI.01583-08. Epub 2008 Oct 15.

PMID:
18922865
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.

Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R.

J Virol. 2009 Jan;83(2):1045-59. doi: 10.1128/JVI.01992-08. Epub 2008 Nov 12.

PMID:
19004942
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.

Bradney AP, Scheer S, Crawford JM, Buchbinder SP, Montefiori DC.

J Infect Dis. 1999 May;179(5):1264-7.

PMID:
10191234
[PubMed - indexed for MEDLINE]
Free Article
6.

Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.

Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, Autran B, Barin F.

AIDS. 2006 Oct 3;20(15):1923-30.

PMID:
16988513
[PubMed - indexed for MEDLINE]
7.
8.

Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).

Bao MJ, Geng WQ, Cui HL, Zhang XL, Xu DB, Nian H, Dai D, Wang YN, Shang H.

Mol Med Rep. 2012 May;5(5):1311-7. doi: 10.3892/mmr.2012.790. Epub 2012 Feb 14.

PMID:
22344547
[PubMed - indexed for MEDLINE]
9.

Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.

Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R, Janssens W, van der Groen G.

J Med Virol. 2000 Sep;62(1):14-24.

PMID:
10935983
[PubMed - indexed for MEDLINE]
10.

Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.

Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, Richardson B, Walker B, Haigwood NL.

J Virol. 2009 Jan;83(2):662-72. doi: 10.1128/JVI.01328-08. Epub 2008 Nov 5.

PMID:
18987151
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H.

J Infect Dis. 2010 Apr 1;201(7):1045-53. doi: 10.1086/651144.

PMID:
20170371
[PubMed - indexed for MEDLINE]
Free Article
12.

Conserved neutralizing epitopes of HIV type 1 CRF01_AE against primary isolates in long-term nonprogressors.

Sreepian A, Srisurapanon S, Horthongkham N, Tunsupasawasdikul S, Kaoriangudom S, Khusmith S, Sutthent R.

AIDS Res Hum Retroviruses. 2004 May;20(5):531-42.

PMID:
15186528
[PubMed - indexed for MEDLINE]
13.

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.

Medina-Ramírez M, Sánchez-Merino V, Sánchez-Palomino S, Merino-Mansilla A, Ferreira CB, Pérez I, González N, Alvarez A, Alcocer-González JM, García F, Gatell JM, Alcamí J, Yuste E.

J Virol. 2011 Jun;85(12):5804-13. doi: 10.1128/JVI.02482-10. Epub 2011 Apr 6.

PMID:
21471239
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC.

J Infect Dis. 1997 Oct;176(4):924-32.

PMID:
9333150
[PubMed - indexed for MEDLINE]
Free Article
15.

Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.

Auewarakul P, Louisirirotchanakul S, Sutthent R, Taechowisan T, Kanoksinsombat C, Wasi C.

Viral Immunol. 1996;9(3):175-85.

PMID:
8890476
[PubMed - indexed for MEDLINE]
16.

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR.

J Virol. 2007 Jun;81(12):6548-62. Epub 2007 Apr 4.

PMID:
17409160
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects.

Cecilia D, Kleeberger C, Muñoz A, Giorgi JV, Zolla-Pazner S.

J Infect Dis. 1999 Jun;179(6):1365-74.

PMID:
10228056
[PubMed - indexed for MEDLINE]
Free Article
18.

Similar neutralizing activity in the HIV-1 infected long term non-progressors(LTNPs) and typical progressors(TPs).

Wang Z, Li TY, Li JY, Chen LL, Liu YJ, Li HP, Bao ZY, Wang XL, Zhuang DM, Liu SY, Li L.

Virol Sin. 2012 Jun;27(3):165-71. doi: 10.1007/s12250-012-3239-8. Epub 2012 Jun 9.

PMID:
22684470
[PubMed - indexed for MEDLINE]
19.

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS.

J Infect Dis. 1996 Feb;173(2):340-8.

PMID:
8568294
[PubMed - indexed for MEDLINE]
Free Article
20.

Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors.

Betts MR, Krowka JF, Kepler TB, Davidian M, Christopherson C, Kwok S, Louie L, Eron J, Sheppard H, Frelinger JA.

AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1219-28.

PMID:
10480635
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk